Airway-aware resuscitation, variceal vs nonvariceal phenotype, urgent endoscopic hemostasis, and escalation to IR/TIPS/surgery when bleeding remains uncontrolled.
Life-threatening upper GI bleeding is defined by physiology and airway/hemodynamic threat rather than a single measured blood-loss threshold. Stabilization should proceed in parallel with rapid identification of likely variceal vs nonvariceal bleeding and mobilization of definitive hemostasis.
Caution
Do not use the initial hemoglobin to rule out major acute hemorrhage. Ongoing hematemesis with impaired airway protection, shock, escalating transfusion requirements, or suspected variceal bleeding requires early gastroenterology and critical-care escalation.
Life-threatening upper GI bleeding: resuscitate, phenotype, control
Resuscitate enough to reach definitive hemostasis; temporizing stabilization must not become a reason to delay source control.
Protect the airway when ongoing hematemesis, encephalopathy or respiratory failure makes aspiration likely.
Establish monitoring and large-bore IV access, obtain type/crossmatch, and activate the local major-hemorrhage protocol when shock or rapid ongoing transfusion warrants it.
Correct clinically important anticoagulant effects when life-threatening bleeding and the specific agent/context justify reversal.
Most stabilized UGIB patients are managed with a restrictive RBC strategy, individualized for active shock, myocardial ischemia, ongoing hemorrhage and comorbidity.
Suspected nonvariceal ulcer bleeding: give IV proton-pump inhibitor therapy according to the local pathway.
Suspected variceal bleeding: start vasoactive therapy plus short-course antibiotic prophylaxis promptly and involve hepatology/GI.
Arrange endoscopy after initial resuscitation, generally within 24 hours for upper GI bleeding; unstable patients and suspected variceal hemorrhage require a more urgent specialist pathway.
Use lesion-appropriate endoscopic hemostatic therapy.
If bleeding persists or recurs, escalate early rather than repeating temporizing resuscitation indefinitely.
Caution
Evidence frame: ACG Upper Gastrointestinal and Ulcer Bleeding guideline (2021) for nonvariceal UGIB and Baveno VII consensus (2022) for portal-hypertensive/variceal bleeding. Local transfusion, reversal and endoscopy pathways remain authoritative.
Evidence status
Review metadata not yet recorded.
Status, review dates and guideline versions appear here once editorial metadata is authored for this content.
From recognizing hypoperfusion and initial crystalloid bolus to dynamic fluid responsiveness assessment and vasopressor targets.
From first-line norepinephrine titration to multi-agent vasopressor escalation and inotrope selection.
From multi-vasopressor failure to rescue non-adrenergic agents and mechanical circulatory support.
From confirming true hypotension to recognizing shock and its likely category.
Risk-stratified non-variceal and variceal hemorrhage care: resuscitation, selective airway protection, individualized transfusion, PPI or portal-pressure therapy, endoscopic hemostasis, and escalation to IR/TIPS/surgery when indicated.
The trauma lethal diamond (hypothermia, acidosis, coagulopathy, hypocalcemia), 1:1:1 massive transfusion (PROPPR trial), early TXA (CRASH-2), and TEG/ROTEM algorithms.
Patient-specific RBC transfusion thresholds, current platelet/procedural thresholds, plasma/cryoprecipitate use, and the TRALI vs TACO diagnostic matrix.
Cellular dysoxia, DO2/VO2 physiology, the 4 shock phenotypes, dynamic fluid responsiveness (PLR/PPV) vs fluid tolerance (VExUS), and vasoactive pharmacology.
UFH vs LMWH vs DTIs (Argatroban/Bivalirudin), anti-Xa vs aPTT monitoring, and emergency reversal (Protamine, 4F-PCC, Idarucizumab; historical andexanet evidence with current availability caveats).
Recognition and organ-support of decompensated cirrhosis and acute-on-chronic liver failure, including bleeding, infection, encephalopathy and transplant triage